InspireMD (NYSE:NSPR) CEO Buys $25,200.00 in Stock

InspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman acquired 21,000 shares of InspireMD stock in a transaction dated Tuesday, May 12th. The shares were acquired at an average price of $1.20 per share, with a total value of $25,200.00. Following the completion of the acquisition, the chief executive officer directly owned 3,556,658 shares of the company’s stock, valued at approximately $4,267,989.60. The trade was a 0.59% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

InspireMD Price Performance

Shares of NYSE NSPR traded down $0.03 during mid-day trading on Wednesday, reaching $1.17. 323,560 shares of the company’s stock traded hands, compared to its average volume of 181,792. The stock has a market cap of $54.80 million, a P/E ratio of -1.56 and a beta of 0.82. The business has a 50-day simple moving average of $1.47 and a 200 day simple moving average of $1.73. InspireMD, Inc. has a 1-year low of $1.02 and a 1-year high of $2.93.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NSPR. Aberdeen Group plc purchased a new position in InspireMD during the third quarter worth about $5,979,000. Rosalind Advisors Inc. boosted its holdings in InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Velan Capital Investment Management LP boosted its holdings in InspireMD by 137.1% during the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock worth $5,166,000 after purchasing an additional 1,239,669 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in InspireMD by 97.6% during the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after purchasing an additional 1,205,328 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its holdings in InspireMD by 45.7% during the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after purchasing an additional 1,058,467 shares during the last quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NSPR. Lake Street Capital set a $4.00 price objective on shares of InspireMD in a report on Monday, May 4th. Maxim Group began coverage on shares of InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Loop Capital set a $5.00 price objective on shares of InspireMD in a report on Tuesday, February 24th. Finally, Piper Sandler reiterated an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD presently has an average rating of “Buy” and an average price target of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.